Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment

NCT06304025 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Graft Versus Host Disease

Interventions

BIOLOGICAL: Wharton's jelly mesenchymal stem cells (WJ-MSCs)

Sponsor

Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

Collaborators

[object Object]